Is Kodiak Sciences (KOD) Fully Valued As AAO 2026 Trial Data Nears?

Kodiak Sciences (KOD) is back in focus after announcing that Phase 3 data for Zenkuda, tabirafusp-ted and early stage KSI-101 will be showcased at the AAO 2026 ophthalmology meeting.

The share price of Kodiak Sciences has cooled slightly in the very short term, with a 1-day move down 1.36% and a 7-day share price return down 3.92%. This follows a sharp 30-day share price return of 157.58% and a year-to-date share price return of 250.04%, leaving momentum still firmly positive overall.

Surf 35 healthcare AI stocks that, like Kodiak Sciences, are tying cutting edge science to data driven pipelines and could be gearing up for their own catalyst heavy conference seasons.

After a 1 year move that runs into very large triple digits and a market value now around US$5.8b, the question for Kodiak Sciences shifts. Does the current valuation still leave a clear edge for new buyers on the risk side versus the potential reward?

Most Popular Narrative: 7% Overvalued

Kodiak Sciences last closed at $91.08 against a widely followed fair value estimate of $85, a modest premium that rests on a very specific pipeline outcome playing out over time under a 7.5% discount rate.

The dual mechanism KSI-501 program, already positive in wet AMD and now being advanced into the global Phase 3 ALTO trial in diabetic macular edema with superiority and extended interval dosing objectives, introduces upside from a second late stage product that analysts may not fully include in longer term revenue and earnings expectations.

See why 0 investors see Kodiak Sciences as 7% overvalued.

Result: Fair Value of $85 (OVERVALUED)

Still, Kodiak Sciences carries meaningful risk if Phase 3 trials underperform expectations or if future funding arrives on dilutive terms that put pressure on existing shareholders.

Find out about the key risks to this Kodiak Sciences narrative.

Another View on Kodiak Sciences’ Valuation

While the fair value narrative pegs Kodiak Sciences at $85 and labels the stock as overvalued on that framework, the SWS DCF model points in a very different direction. It suggests the shares trade well below an estimated future cash flow value of $737.08. Which lens do you trust when the gap is this wide?

For readers who want to see how this cash flow driven approach is built and stress tested, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kodiak Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 29 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Big moves and split valuations can spark excitement around Kodiak Sciences, but they also create pressure to decide quickly where you stand. If you want a clearer picture of both the upside and the downside, weigh the 3 key rewards and 4 important warning signs.

Looking for more ideas beyond Kodiak Sciences?

If Kodiak Sciences has your attention, do not stop there. The market keeps moving and you may miss real opportunities if you only watch one ticker.

Scan for potential value opportunities by reviewing companies flagged in the 29 high quality undervalued stocks that pair quality fundamentals with discounted prices.

Prioritize resilience by checking out a curated 31 resilient stocks with low risk scores that may suit investors who want fewer surprises when volatility spikes.

Hunt for future market leaders by investigating the 20 high quality undiscovered gems before they land on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com